Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07523711 · ClinicalTrials.gov registry record · Phase 1
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
A Phase 1 study, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT07523711: Recruiting Phase 1 study, sponsored by Amgen.
NCT07523711 is a Phase 1 study that is actively recruiting participants, run by Amgen. The registered enrollment target is 45 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07523711, a Phase 1 study, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The primary objective of the trial is to evaluate the effect of maridebart cafraglutide on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in postmenopausal female participants living with overweight or obesity.
Interventions
- DRUG Maridebart Cafraglutide
- DRUG COC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-04-09 |
| Est. Completion | 2026-11-18 |
| Phase | Phase 1 |
What NCT07523711 shows while recruiting
NCT07523711 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 2 interventions - of which Maridebart Cafraglutide is the first listed.
NCT07523711 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07523711 about?
NCT07523711 is a clinical study titled "Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity". The primary objective of the trial is to evaluate the effect of maridebart cafraglutide on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in postmenopausal female participants living with overweight or obesity.
What is the current status of trial NCT07523711?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2026-04-09. Estimated completion is 2026-11-18.
What interventions are being tested in trial NCT07523711?
The interventions under investigation include: Maridebart Cafraglutide (DRUG), COC (DRUG).
Who is sponsoring clinical trial NCT07523711?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07523711's enrollment target sits among peer trials
45 1066th of 2000 higher than 915 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI